News - YM Biosciences


Current filters:

YM Biosciences

Popular Filters

Gilead agrees to buy YM BioSciences for $510 million


US biotech firm Gilead Sciences (Nasdaq: GILD) has agreed to acquire Canada's YM BioSciences (TSX: YM)…

BiotechnologyCYT387Gilead SciencesMergers & AcquisitionsOncologyPharmaceuticalYM Biosciences

News briefs on Ipsen/Galderma and YM BioSciences nimotuzumab assets


French drugmaker Ipsen (Euronext: IPN) and Switzerland-headquartered Galderma have expanded their collaboration…

Asia-PacificBiotechnologyCIMABDysportGaldermaInnoKeys PTEIpsenLicensingnimotuzumabOncologyPharmaceuticalSouth AmericaYM Biosciences

YM BioSciences - to partner or not to partner?


Canadian firm biotechnology firm YM BioSciences' (TSX: YM) conundrum of whether to partner or go it alone…

BiotechnologyCYT387FinancialLicensingResearchYM Biosciences

Bargaining power boost for YM BioSciences


The share offering last week by Canadian firm biotechnology firm YM BioSciences (TSX: YM), which raised…

BiotechnologyFinancialOncologyResearchYM Biosciences

YM Biosciences investment case centers on CYT387; analysts view


The oral JAK1/2 inhibitor CYT387 has emerged as Canada-based YM BioSciences’ (TSX: YM) lead development…

FinancialOncologyPharmaceuticalResearchYM Biosciences

Back to top